This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012 Sep;23 Suppl 8:viii6-9.FinnOJImmuno-oncology: understanding the function and dysfunction of the immune system in cancerAnn Oncol2012Sep23Suppl 8viii6910.1093/annonc/mds256Search in Google Scholar
Eggermont A, Finn O. Advances in immuno-oncology. Foreword. Ann Oncol. 2012 Sep;23 Suppl 8:viii5.EggermontAFinnOAdvances in immuno-oncologyForeword. Ann Oncol2012Sep23Suppl 8viii510.1093/annonc/mds255Search in Google Scholar
Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy--revisited. Nat Rev Drug Discov. 2011 Aug;10(8):591-600.LesterhuisWJHaanenJBPuntCJCancer immunotherapy--revisitedNat Rev Drug Discov2011Aug10859160010.1038/nrd3500Search in Google Scholar
Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991 Sep 1;174(3):561-9.LinsleyPSBradyWUrnesMGrosmaireLSDamleNKLedbetterJACTLA-4 is a second receptor for the B cell activation antigen B7J Exp Med1991Sep 11743561910.1084/jem.174.3.561Search in Google Scholar
Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014 Jul;21(3):231-7.DolanDEGuptaSPD-1 pathway inhibitors: changing the landscape of cancer immunotherapyCancer Control2014Jul213231710.1177/107327481402100308Search in Google Scholar
Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response. Clin Cancer Res. 2013 Oct 1;19(19):5542.SznolMChenLAntagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--responseClin Cancer Res2013Oct 11919554210.1158/1078-0432.CCR-13-2234Search in Google Scholar
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23.HodiFSO’DaySJMcDermottDFWeberRWSosmanJAHaanenJBet alImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010Aug 1936387112310.1056/NEJMoa1003466Search in Google Scholar
Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26.RobertCThomasLBondarenkoIO’DaySWeberJGarbeCet alIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011Jun 303642625172610.1056/NEJMoa1104621Search in Google Scholar
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Jul 2;373(1):23-34.LarkinJChiarion-SileniVGonzalezRGrobJJCoweyCLLaoCDet alCombined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaN Engl J Med2015Jul 23731233410.1056/NEJMoa1504030Search in Google Scholar
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 May;16(5):522-30.EggermontAMChiarion-SileniVGrobJJDummerRWolchokJDSchmidtHet alAdjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialLancet Oncol2015May1655223010.1016/S1470-2045(15)70122-1Search in Google Scholar
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jun;15(7):700-12.KwonEDDrakeCGScherHIFizaziKBossiAvan den EertweghAJet alIpilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialLancet Oncol2014Jun1577001210.1016/S1470-2045(14)70189-5Search in Google Scholar
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320-30.RobertCLongGVBradyBDutriauxCMaioMMortierLet alNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015Jan 2237243203010.1056/NEJMoa1412082Search in Google Scholar
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35.BrahmerJReckampKLBaasPCrinoLEberhardtWEPoddubskayaEet alNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerN Engl J Med2015Jul 937321233510.1056/NEJMoa1504627Search in Google Scholar
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39.BorghaeiHPaz-AresLHornLSpigelDRSteinsMReadyNEet alNivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerN Engl J Med2015Oct 223731716273910.1056/NEJMoa1507643Search in Google Scholar
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13.MotzerRJEscudierBMcDermottDFGeorgeSHammersHJSrinivasSet alNivolumab versus Everolimus in Advanced Renal-Cell CarcinomaN Engl J Med2015Nov 53731918031310.1056/NEJMoa1510665Search in Google Scholar
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015 Jan 22;372(4):311-9.AnsellSMLesokhinAMBorrelloIHalwaniAScottECGutierrezMet alPD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphomaN Engl J Med2015Jan 223724311910.1056/NEJMoa1411087Search in Google Scholar
Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015 Jan;27(1):39-46.PhilipsGKAtkinsMTherapeutic uses of anti-PD-1 and anti-PD-L1 antibodiesInt Immunol2015Jan271394610.1093/intimm/dxu095Search in Google Scholar
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32.RobertCSchachterJLongGVAranceAGrobJJMortierLet alPembrolizumab versus Ipilimumab in Advanced MelanomaN Engl J Med2015Jun 253722625213210.1056/NEJMoa1503093Search in Google Scholar
Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015 Dec 18.HerbstRSBaasPKimDWFelipEPerez-GraciaJLHanJYet alPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2015Dec 1810.1016/S0140-6736(15)01281-7Search in Google Scholar
Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012 Jul 20;30(21):2691-7.WeberJSKahlerKCHauschildAManagement of immune-related adverse events and kinetics of response with ipilimumabJ Clin Oncol2012Jul 2030212691710.1200/JCO.2012.41.675022614989Search in Google Scholar
O’Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Aug;21(8):1712-7.O’DaySJMaioMChiarion-SileniVGajewskiTFPehambergerHBondarenkoINet alEfficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnn Oncol2010Aug2181712710.1093/annonc/mdq013Search in Google Scholar
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54.TopalianSLHodiFSBrahmerJRGettingerSNSmithDCMcDermottDFet alSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012Jun 283662624435410.1056/NEJMoa1200690Search in Google Scholar
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug;16(8):908-18.RibasAPuzanovIDummerRSchadendorfDHamidORobertCet alPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol2015Aug1689081810.1016/S1470-2045(15)00083-2Search in Google Scholar
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109-17.RobertCRibasAWolchokJDHodiFSHamidOKeffordRet alAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet2014Sep 20384994811091710.1016/S0140-6736(14)60958-2Search in Google Scholar
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014 Apr 1;32(10):1020-30.TopalianSLSznolMMcDermottDFKlugerHMCarvajalRDSharfmanWHet alSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabJ Clin Oncol2014Apr 1321010203010.1200/JCO.2013.53.0105Search in Google Scholar
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016 Mar;44:51-60.SpainLDiemSLarkinJManagement of toxicities of immune checkpoint inhibitorsCancer Treat Rev2016Mar44516010.1016/j.ctrv.2016.02.001Search in Google Scholar
Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, et al. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res. 2015 May;3(5):464-9.JohnsonDBFriedmanDLBerryEDeckerIYeFZhaoSet alSurvivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral CenterCancer Immunol Res2015May35464910.1158/2326-6066.CIR-14-0217Search in Google Scholar
Squibb BM. Yervoy (Ipilimumab) Product Information, 2015.SquibbBMYervoy (Ipilimumab) Product Information2015Search in Google Scholar
Merck Sharp & Dohme Corp. Keytruda (Pembrolizumab) Product Information, 2015.MerckSharpDohmeCorpKeytruda (Pembrolizumab) Product Information2015Search in Google Scholar
Wolchok JD, Weber JS, Hamid O, Lebbe C, Maio M, Schadendorf D, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9.WolchokJDWeberJSHamidOLebbeCMaioMSchadendorfDet alIpilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trialsCancer Immun2010109Search in Google Scholar
Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.BermanDParkerSMSiegelJChasalowSDWeberJGalbraithSet alBlockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanomaCancer Immun20101011Search in Google Scholar
Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013 May;200(5):W468-74.KimKWRamaiyaNHKrajewskiKMShinagareABHowardSAJagannathanJPet alIpilimumab-associated colitis: CT findingsAJR Am J Roentgenol2013May2005W4687410.2214/AJR.12.9751Search in Google Scholar
Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-84.WeberJSD’AngeloSPMinorDHodiFSGutzmerRNeynsBet alNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol2015Apr1643758410.1016/S1470-2045(15)70076-8Search in Google Scholar
Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013 Dec 1;31(34):4311-8.WeberJSKudchadkarRRYuBGallensteinDHorakCEInzunzaHDet alSafety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanomaJ Clin Oncol2013Dec 131344311810.1200/JCO.2013.51.4802383709224145345Search in Google Scholar
Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015 Oct;4(5):560-75.VilladolidJAminAImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicitiesTransl Lung Cancer Res2015Oct4556075Search in Google Scholar
Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013 Jun;18(6):733-43.FecherLAAgarwalaSSHodiFSWeberJSIpilimumab and its toxicities: a multidisciplinary approachOncologist2013Jun1867334310.1634/theoncologist.2012-0483406340123774827Search in Google Scholar
Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm. 2009 Jun;24(3):321-5.MinorDRChinKKashani-SabetMInfliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitisCancer Biother Radiopharm2009Jun243321510.1089/cbr.2008.060719538054Search in Google Scholar
Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book. 2012:174-7.WeberJSPractical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologistAm Soc Clin Oncol Educ Book2012174710.14694/EdBook_AM.2012.32.7924451730Search in Google Scholar
Ludlow SP, Kay N. Delayed dermatologic hypersensitivity reaction secondary to ipilimumab. J Immunother. 2015 May;38(4):165-6.LudlowSPKayNDelayed dermatologic hypersensitivity reaction secondary to ipilimumabJ Immunother2015May384165610.1097/CJI.000000000000007625839442Search in Google Scholar
Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2016 Apr 12.NaidooJPageDBLiBTConnellLCSchindlerKLacoutureMEet alToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnn Oncol2016Apr 1210.1093/annonc/mdw141500611427072927Search in Google Scholar
Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol. 2016 Jan;152(1):45-51.HuaCBoussemartLMateusCRoutierEBoutrosCCazenaveHet alAssociation of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With PembrolizumabJAMA Dermatol2016Jan1521455110.1001/jamadermatol.2015.270726501224Search in Google Scholar
Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7.HodiFSMihmMCSoifferRJHaluskaFGButlerMSeidenMVet alBiologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsProc Natl Acad Sci U S A2003Apr 1510084712710.1073/pnas.083099710015362112682289Search in Google Scholar
Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs. 2013 Aug;31(4):1071-7.KimKWRamaiyaNHKrajewskiKMJagannathanJPTirumaniSHSrivastavaAet alIpilimumab associated hepatitis: imaging and clinicopathologic findingsInvest New Drugs2013Aug3141071710.1007/s10637-013-9939-623408334Search in Google Scholar
Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013 Apr;98(4):1361-75.CorselloSMBarnabeiAMarchettiPDe VecchisLSalvatoriRTorinoFEndocrine side effects induced by immune checkpoint inhibitorsJ Clin Endocrinol Metab2013Apr98413617510.1210/jc.2012-407523471977Search in Google Scholar
Corsello SM, Salvatori R, Barnabei A, De Vecchis L, Marchetti P, Torino F. Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). Cancer Chemother Pharmacol. 2013 Aug;72(2):489-90.CorselloSMSalvatoriRBarnabeiADe VecchisLMarchettiPTorinoFIpilimumab-induced endocrinopathies: when to start corticosteroids (or not)Cancer Chemother Pharmacol2013Aug7224899010.1007/s00280-013-2213-y23779068Search in Google Scholar
Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol. 2016 Apr 28.TorinoFCorselloSMSalvatoriREndocrinological side-effects of immune checkpoint inhibitorsCurr Opin Oncol2016Apr 2810.1097/CCO.0000000000000293Search in Google Scholar
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10;31(5):616-22.RibasAKeffordRMarshallMAPuntCJHaanenJBMarmolMet alPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaJ Clin Oncol2013Feb 103156162210.1200/JCO.2012.44.6112Search in Google Scholar
Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015 Jun 20;33(18):2092-9.WeberJSYangJCAtkinsMBDisisMLToxicities of Immunotherapy for the PractitionerJ Clin Oncol2015Jun 2033182092910.1200/JCO.2014.60.0379Search in Google Scholar
Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014 Apr;21(2):371-81.RyderMCallahanMPostowMAWolchokJFaginJAEndocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionEndocr Relat Cancer2014Apr2123718110.1530/ERC-13-0499Search in Google Scholar
Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13(1):29-38.DillardTYedinakCGAlumkalJFleseriuMAnti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypesPituitary2010131293810.1007/s11102-009-0193-zSearch in Google Scholar
Tabchi S, Messier C, Blais N. Immune-mediated respiratory adverse events of checkpoint inhibitors. Curr Opin Oncol. 2016 Jun 30.TabchiSMessierCBlaisNImmune-mediated respiratory adverse events of checkpoint inhibitorsCurr Opin Oncol2016Jun 3010.1097/CCO.0000000000000291Search in Google Scholar
Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015 Mar;16(3):257-65.RizviNAMazieresJPlanchardDStinchcombeTEDyGKAntoniaSJet alActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLancet Oncol2015Mar1632576510.1016/S1470-2045(15)70054-9Search in Google Scholar
Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, et al. Kidney injuries related to ipilimumab. Invest New Drugs. 2014 Aug;32(4):769-73.IzzedineHGueutinVGharbiCMateusCRobertCRoutierEet alKidney injuries related to ipilimumabInvest New Drugs2014Aug3247697310.1007/s10637-014-0092-724687600Search in Google Scholar
Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009 Jul 9;361(2):211-2.FadelFEl KarouiKKnebelmannBAnti-CTLA4 antibody-induced lupus nephritisN Engl J Med2009Jul 93612211210.1056/NEJMc090428319587352Search in Google Scholar
Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745.VoskensCJGoldingerSMLoquaiCRobertCKaehlerKCBerkingCet alThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkPLoS One201381e5374510.1371/journal.pone.0053745354490623341990Search in Google Scholar
Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004 Nov-Dec;27(6):478-9.RobinsonMRChanCCYangJCRubinBIGraciaGJSenHNet alCytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitisJ Immunother2004Nov-Dec276478910.1097/00002371-200411000-0000815534492Search in Google Scholar
Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011 Apr;22(4):991-3.WilgenhofSNeynsBAnti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patientAnn Oncol2011Apr224991310.1093/annonc/mdr02821357649Search in Google Scholar
Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother. 2009 Apr;32(3):322-4.AkhtariMWallerEKJayeDLLawsonDHIbrahimRPapadopoulosNEet alNeutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody)J Immunother2009Apr323322410.1097/CJI.0b013e31819aa40b19242368Search in Google Scholar
Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother. 2009 Aug;58(8):1351-3.GordonIOWadeTChinKDicksteinJGajewskiTFImmune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanomaCancer Immunol Immunother2009Aug5881351310.1007/s00262-008-0627-x19052742Search in Google Scholar
Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8.DowneySGKlapperJASmithFOYangJCSherryRMRoyalREet alPrognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockadeClin Cancer Res2007Nov 15; 13(22 Pt 1)6681810.1158/1078-0432.CCR-07-0187214708317982122Search in Google Scholar
Weber J AS, Topalian SL, Schadendorf D, Larkin J, Sznol M, Liu HY, Waxman I, Robert C. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol 33, 2015 (suppl; abstr 9018).WeberJ ASTopalianSLSchadendorfDLarkinJSznolMLiuHYWaxmanIRobertCSafety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysisJ Clin Oncol332015(suppl; abstr 9018)10.1200/jco.2015.33.15_suppl.9018Search in Google Scholar
